胃肠间质瘤靶向药物的治疗药物监测中国专家共识

2021-08-19 中国医院药学杂志

治疗药物监测（therapeutic drug monitoring, TDM）是一门研究个体化药物治疗机制、技术、方法和临床标准，并将研究结果转化应用于临床治疗以达到最大化合理用药的药学临床学科，通

中文标题：

发布机构：

发布日期：

2021-08-19

简要介绍：

治疗药物监测（therapeutic drug monitoring, TDM）是一门研究个体化药物治疗机制、技术、方法和临床标准，并将研究结果转化应用于临床治疗以达到最大化合理用药的药学临床学科，通过测定患者体内的药物暴露量、药理学标志物或药效学指标，利用定量药理模型，以药物治疗窗为基准，制订适合患者的个体化给药方案，其核心是个体化药物治疗。为促进GIST靶向药物的TDM规范化，推动GIST精准治疗和全程化管理，中国药学会医院药学专委会牵头组成团队，参考国内外最新研究进展，制定本共识。鉴于目前国内外GIST靶向药物TDM的研究资料主要集中在伊马替尼和舒尼替尼，本共识暂以二者为重点展开。

相关资料下载：

GetToolGuiderByIdResponse(projectId=1, id=c58991c00216662e, title=胃肠间质瘤靶向药物的治疗药物监测中国专家共识, enTitle=, guiderFrom=中国医院药学杂志, authorId=0, author=, summary=治疗药物监测（therapeutic drug monitoring, TDM）是一门研究个体化药物治疗机制、技术、方法和临床标准，并将研究结果转化应用于临床治疗以达到最大化合理用药的药学临床学科，通, cover=https://img.medsci.cn/2021829/1630247456985_2020535.jpg, journalId=0, articlesId=null, associationId=0, associationName=, associationIntro=, copyright=0, guiderPublishedTime=Thu Aug 19 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=治疗药物监测（therapeutic drug monitoring, TDM）是一门研究个体化药物治疗机制、技术、方法和临床标准，并将研究结果转化应用于临床治疗以达到最大化合理用药的药学临床学科，通过测定患者体内的药物暴露量、药理学标志物或药效学指标，利用定量药理模型，以药物治疗窗为基准，制订适合患者的个体化给药方案，其核心是个体化药物治疗。为促进GIST靶向药物的TDM规范化，推动GIST精准治疗和全程化管理，中国药学会医院药学专委会牵头组成团队，参考国内外最新研究进展，制定本共识。鉴于目前国内外GIST靶向药物TDM的研究资料主要集中在伊马替尼和舒尼替尼，本共识暂以二者为重点展开。, tagList=[TagDto(tagId=1248, tagName=胃肠间质瘤)], categoryList=[CategoryDto(categoryId=4, categoryName=消化, tenant=100), CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=1248, guiderKeyword=胃肠间质瘤, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=3662, appHits=158, showAppHits=0, pcHits=427, showPcHits=3503, likes=1, shares=18, comments=4, approvalStatus=1, publishedTime=Sun Aug 29 22:36:14 CST 2021, publishedTimeString=2021-08-19, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Sun Aug 29 22:31:08 CST 2021, updatedBy=2020535, updatedName=qiushida2, updatedTime=Sat Jan 06 18:45:24 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=胃肠间质瘤靶向药物的治疗药物监测中国专家共识_张玉.pdf)])

胃肠间质瘤靶向药物的治疗药物监测中国专家共识_张玉.pdf

下载请点击：

评论区 (4)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=1085487, encodeId=11c3108548e2e, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2cd5399260, createdName=ms3000000121177566, createdTime=Wed Dec 29 16:15:30 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066546, encodeId=c7611066546e7, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90553936587, createdName=138e6326m88暂无昵称, createdTime=Wed Nov 03 11:07:00 CST 2021, time=2021-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1065883, encodeId=20e8106588338, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8a35439329, createdName=ms3000000920707852, createdTime=Mon Nov 01 19:06:55 CST 2021, time=2021-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1015776, encodeId=9f441015e76e5, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22075450427, createdName=ms2000001530004019, createdTime=Wed Sep 08 20:22:57 CST 2021, time=2021-09-08, status=1, ipAttribution=)]
2021-12-29 ms3000000121177566

学习

48 0
[GetPortalCommentsPageByObjectIdResponse(id=1085487, encodeId=11c3108548e2e, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2cd5399260, createdName=ms3000000121177566, createdTime=Wed Dec 29 16:15:30 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066546, encodeId=c7611066546e7, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90553936587, createdName=138e6326m88暂无昵称, createdTime=Wed Nov 03 11:07:00 CST 2021, time=2021-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1065883, encodeId=20e8106588338, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8a35439329, createdName=ms3000000920707852, createdTime=Mon Nov 01 19:06:55 CST 2021, time=2021-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1015776, encodeId=9f441015e76e5, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22075450427, createdName=ms2000001530004019, createdTime=Wed Sep 08 20:22:57 CST 2021, time=2021-09-08, status=1, ipAttribution=)]
2021-11-03 138e6326m88暂无昵称

学习

67 0
[GetPortalCommentsPageByObjectIdResponse(id=1085487, encodeId=11c3108548e2e, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2cd5399260, createdName=ms3000000121177566, createdTime=Wed Dec 29 16:15:30 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066546, encodeId=c7611066546e7, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90553936587, createdName=138e6326m88暂无昵称, createdTime=Wed Nov 03 11:07:00 CST 2021, time=2021-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1065883, encodeId=20e8106588338, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8a35439329, createdName=ms3000000920707852, createdTime=Mon Nov 01 19:06:55 CST 2021, time=2021-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1015776, encodeId=9f441015e76e5, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22075450427, createdName=ms2000001530004019, createdTime=Wed Sep 08 20:22:57 CST 2021, time=2021-09-08, status=1, ipAttribution=)]
2021-11-01 ms3000000920707852

学习

78 0
[GetPortalCommentsPageByObjectIdResponse(id=1085487, encodeId=11c3108548e2e, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2cd5399260, createdName=ms3000000121177566, createdTime=Wed Dec 29 16:15:30 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066546, encodeId=c7611066546e7, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90553936587, createdName=138e6326m88暂无昵称, createdTime=Wed Nov 03 11:07:00 CST 2021, time=2021-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1065883, encodeId=20e8106588338, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8a35439329, createdName=ms3000000920707852, createdTime=Mon Nov 01 19:06:55 CST 2021, time=2021-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1015776, encodeId=9f441015e76e5, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22075450427, createdName=ms2000001530004019, createdTime=Wed Sep 08 20:22:57 CST 2021, time=2021-09-08, status=1, ipAttribution=)]
2021-09-08 ms2000001530004019

学习学习

97 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

消化指南

胃肠间质瘤靶向药物的治疗药物监测中国专家共识

相关指南

拓展阅读

科室

工具

服务